Begleittherapie bei Cisplatin

Bokemeyer, Carsten; Sökler, Martin; Schmoll, H.-J.; Sauer, H

doi:10.1007/3-540-31303-6_141

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately the clinical success of Cisplatin is limited by its severe side effects, which include nephrotoxicity, cumulative neurotoxicity, ototoxicity, and extreme emetogenic potential [4][5][6]. Another major factor compromising its clinical usefulness is the development of acquired or primary resistance of malignant cells [7][8][9]. Thus much attention has been focussed on designing Cisplatin analogues with reduced toxicity and a broader antitumor spectrum [9,11].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and crystal structure of a Pt(II) complex with 3-amino-5-methyl-5-phenylhydantoin

Bakalova

Petrova

Shivachev

et al. 2007

Journal of Coordination Chemistry

View full text Add to dashboard Cite

The reaction of K 2 PtCl 4 with 3-amino-5-methyl-5-phenylhydantoin (amphh, L) and KI in aqueous ethanol yields dark violet crystals of a binuclear platinum(II) complex. The molecular structure of the complex was determined by single-crystal X-ray diffraction methods. The complex crystallizes in the triclinic space group P 1 with a ¼ 8.458 (3), b ¼ 11.016(2), c ¼ 16.249(3) (Å ), ¼ 94.630(14), ¼ 100.63(2), ¼ 108.55(4) and Z ¼ 2. The structure consists of [K 2 L 4 ] 2þ cations and [Pt 2 I 6 ] 2À anions bridged by K-I bonds to form quasione-dimensional chains along the b axis. Chains are linked by K þ Á Á Á (Ph) interactions and N-H Á Á Á O hydrogen bonds. The complex is compared with data for related structures.

show abstract